447 related articles for article (PubMed ID: 22025459)
1. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
7. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
[TBL] [Abstract][Full Text] [Related]
9. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[TBL] [Abstract][Full Text] [Related]
11. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
13. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M;
J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416
[TBL] [Abstract][Full Text] [Related]
15. Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.
Mesaros S; Rocca M; Sormani M; Valsasina P; Markowitz C; De Stefano N; Montalban X; Barkhof F; Ranjeva J; Sailer M; Kappos L; Comi G; Filippi M
Mult Scler; 2010 Mar; 16(3):325-31. PubMed ID: 20086023
[TBL] [Abstract][Full Text] [Related]
16. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
[TBL] [Abstract][Full Text] [Related]
17. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
20. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]